EMEND 125 MG POWDER PACKET

What it is

EMEND 125 MG POWDER PACKET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as aprepitant, under the trade name “EMEND”.

FDA gives its dosage form as powder, for suspension and its route as oral.

The labeler, the company named on the label, is Merck Sharp & Dohme LLC.

FDA’s Established Pharmacologic Class for it is Substance P/Neurokinin-1 Receptor Antagonist.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $327.38 for 1 unit (EA) (1 × $327.384 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · NADAC explanation codes

All 2 NDCs

• 00006-3066-01 · not listed as a package in the FDA directory · $327.384 per EA · eff. 2026-09-23 filed
• 00006-3066-03 · Merck Sharp & Dohme LLC · $327.384 per EA · eff. 2026-09-23 filed

Other strengths, forms and brands

4 other products in the NADAC file share the FDA nonproprietary name aprepitant with EMEND 125 MG POWDER PACKET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $327.384 per EA filed.

Of the 3 other products in FDA’s Substance P/Neurokinin-1 Receptor Antagonist class priced per EA, 0 have a higher middle NADAC price and 3 a lower one. The one in the middle is APREPITANT 80 MG CAPSULE, at $76.35243 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J8501, for 2026-10-01 to 2026-12-31, comes to $62.78 for 1 unit (EA), or $62.775 per EA once converted to NADAC’s unit for this product.

Medicare Part B pays for this oral drug at a pharmacy only in specific circumstances CMS sets for this code; most prescriptions are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $0.5022 per 5 MG.

1 of the product’s 2 NDCs have this Medicare figure; the other 1 do not, and the interactive card says why for each.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 1 unit (EA)? Is it lower than what I would pay through my insurance?
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.